Clinical Trial Update: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ficlatuzumab with or without cetuximab in cetuximab-resistant recurrent or metastatic head and neck squamous cell carcinoma; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Lip and Oral Cavity Squamous Cell Carcinoma
• Nasopharyngeal Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Paranasal Sinus Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Unknown Primary Origin

Drugs mentioned

• Cetuximab (cetuximab)
• Ficlatuzumab (ficlatuzumab)

Snippet

Sponsor: University of Arizona | Conditions: Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-07-19